Obstructive lung disease treatment developer Nuvaira announced that Tom Griffin joined the company as its new chief financial officer.
Griffin has a 30-year record of leadership roles that included guiding companies through investment financing, commercialization growth and IPO stages, according to a news release. He most recently served as CFO at Avedro, which completed its IPO in February 2019 and was acquired by Glaukos in November 2019.
Before Avedro, Griffin held the CFO role at Entellus Medical (NSDQ:ENTL) for approximately nine years and guided the company through its IPO in 2015 before Stryker (NYSE:SYK) acquired the company for $664 million in February 2018.
“We are thrilled that Tom has joined our team,” Nuvaira CEO Dr. Dennis Wahr said in the news release. “His experience guiding start-up medical device companies through the critical clinical development phase with successful transition to commercial growth and public market offerings will be critical to Nuvaira’s continued progress and success.”
Griffin added that Nuvaira has an exciting vision for development of its therapy.
Nuvaira develops the dNerva lung denervation system designed to address airway hyper-responsiveness in chronic obstructive pulmonary disease (COPD) and asthma. Currently, the company’s Airflow-3 pivotal trial is enrolling patients in the U.S., Canada and Europe. It just reached the 50-patient enrollment milestone, according to the news release.